Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
ln Vitro |
LL-37, human acetate (1 -20 μg/mL; 24 h) have an impact on HCEC migration [2]. Human acetate, LL-37 (0.0001–5 μg/mL; 6–24 h), influences the release of cytokines in HCECs [2]. At a concentration over 10 μg/mL, LL-37, human acetate (1-100 μg/mL; 24 h), demonstrates dose-dependent cytotoxicity to HCECs [2].
|
---|---|
ln Vivo |
MRSA-induced pneumonia in mice is ameliorated by LL-37, human acetate (0.4-2.0 mg/kg; intratracheal injection once) [3].
|
Cell Assay |
Cell Migration Assay [2]
Cell Types: Human corneal epithelial cell(HCEC) Tested Concentrations: 1, 2.5, 5, 10 and 20 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Dose-dependently stimulated HCEC migration but demonstrated no effect on cell proliferation. Cell Viability Assay[2] Cell Types: Human corneal epithelial cell(HCEC) Tested Concentrations: 0.0001, 0.001, 0.01, 0.1, 0.5, 1, and 5 μg/mL Incubation Duration: 6 and 24 hrs (hours) Experimental Results: Dose-dependently increased IL -8, IL-6, IL-1β and TNF-α secretion at 6 and 24 hrs (hours) in HCEC. |
Animal Protocol |
Animal/Disease Models: 6-8 week-old C57BL/6 mice with MRSA-induced pneumonia[3]
Doses: 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg Route of Administration: Intracheal injection; 0.4-2.0 mg/kg once Experimental Results: diminished IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice. |
References |
[1]. Dürr UH, et al. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006 Sep;1758(9):1408-25.
[2]. Huang LC, et al. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2369-80. [3]. Hou M, et al. Antimicrobial peptide LL-37 and IDR-1 ameliorate MRSA pneumonia in vivo. Cell Physiol Biochem. 2013;32(3):614-23. |
Molecular Formula |
C205H340N60O53.XC2H4O2
|
---|---|
Molecular Weight |
4493.26 (free base)
|
Related CAS # |
LL-37, human;154947-66-7;LL-37, human TFA
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O :~100 mg/mL
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.